Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Can Radiotherapy Quality Assurance (RT QA) improve nasopharyngeal cancer outcomes in low- and middle-income countries (LMICs) - Reporting the technical component of the second phase of a prospective International Atomic Energy Agency (IAEA) study (E33039).

Can Radiotherapy Quality Assurance (RT QA) improve nasopharyngeal cancer outcomes in low- and middle-income countries (LMICs) - Reporting the technical component of the second phase of a prospective International Atomic Energy Agency (IAEA) study (E33039). International journal of radiation oncology, biology, physics Corry, J., Ng, W. T., Moore, A., Choi, H. C., Le, Q. T., Holmes, S., Munandar, A., Wang, S., Camacho, A., Setakornnukul, J., Jiarpinitnun, C., Hiep, P. N., Laskar, S. G., Faheem, M., Ammar, C. N., Fidarova, E., Hopkins, K., Rosenblatt, E., Abdel-Wahab, M., Lee, A. W. 2025

Abstract

Can Radiotherapy Quality Assurance (RT QA) improve nasopharyngeal cancer (NPC) outcomes in low- and middle-income countries (LMICs) -Reporting phase 2 of a prospective International Atomic Energy Agency (IAEA) study (E33039).Most of new NPC cases occur in LMICs, but these patients experience poorer survival than new NPC cases in high income countries. This study seeks to determine whether a radiotherapy quality assurance (RT QA) programme can improve NPC patient outcomes in LMICs. Here we report the technical results of the second phase of the International E33039 study.Phase 1 of this study included an audit by an expert panel of 134 NPC patients' radiotherapy plans from LMICs. It was previously reported and showed a 64% rate of unacceptable plans. Detailed RT QA reports was given to each center, followed by an educational face-to-face workshop discussing the results and improvement plans. Thereafter accrual for phase 2 commenced. The primary endpoint of the technical component of phase 2 is the number of major deviations in Priority 1 Parameters as compared to phase 1.153 patients accrued from 9 centers between April 2020 and April 2023 in Phase 2. 105 (68.6%) were reviewed pre-treatment as per protocol, and 48 (31.4%) were reviewed post treatment (not per protocol, due to technical reasons). Of the plans reviewed pretreatment, 31/105 (29.5%) were unacceptable due to major deviations in priority one structures. Thirty cases (30/31, 96.8%) were resubmitted and 20 were deemed acceptable (an improvement of 20/30, 66.7%). Of the plans reviewed posttreatment, 6/48 (12.5%) were unacceptable. The overall rate of unacceptable plan was 11% (17/153) in Phase 2 compared with 64% in phase 1.This prospective study shows that RT QA and education for NPC radiotherapy plans in LMICs can dramatically reduce major RT protocol deviations. This will hopefully translate into improved patient outcomes.

View details for DOI 10.1016/j.ijrobp.2025.08.057

View details for PubMedID 40915434